[Anti-hypertensive effect of the angiotensin II antagonist saralasin acetate, a diagnostic criterion of renovascular hypertension]. 1978

F Wessels, and H Wagner, and R Erhard, and P Peters, and H Losse

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D006977 Hypertension, Renal Persistent high BLOOD PRESSURE due to KIDNEY DISEASES, such as those involving the renal parenchyma, the renal vasculature, or tumors that secrete RENIN. Hypertensions, Renal,Renal Hypertension,Renal Hypertensions
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine
D012504 Saralasin An octapeptide analog of angiotensin II (bovine) with amino acids 1 and 8 replaced with sarcosine and alanine, respectively. It is a highly specific competitive inhibitor of angiotensin II that is used in the diagnosis of HYPERTENSION. 1-Sar-8-Ala Angiotensin II,1-Sarcosine-8-Alanine Angiotensin II,(Sar(1),Ala(8))ANGII,(Sar1,Val5,Ala8)Angiotensin II,Angiotensin II, Sar(1)-Ala(8)-,Angiotensin II, Sarcosyl(1)-Alanine(8)-,Sar-Arg-Val-Tyr-Val-His-Pro-Ala,Saralasin Acetate,Saralasin Acetate, Anhydrous,Saralasin Acetate, Hydrated,1 Sar 8 Ala Angiotensin II,1 Sarcosine 8 Alanine Angiotensin II,Angiotensin II, 1-Sar-8-Ala,Angiotensin II, 1-Sarcosine-8-Alanine,Anhydrous Saralasin Acetate,Hydrated Saralasin Acetate

Related Publications

F Wessels, and H Wagner, and R Erhard, and P Peters, and H Losse
January 1977, Verhandlungen der Deutschen Gesellschaft fur Kreislaufforschung,
F Wessels, and H Wagner, and R Erhard, and P Peters, and H Losse
March 1975, The New England journal of medicine,
F Wessels, and H Wagner, and R Erhard, and P Peters, and H Losse
December 1978, La Nouvelle presse medicale,
F Wessels, and H Wagner, and R Erhard, and P Peters, and H Losse
December 1976, Schweizerische medizinische Wochenschrift,
F Wessels, and H Wagner, and R Erhard, and P Peters, and H Losse
July 1974, Journal of pharmaceutical sciences,
F Wessels, and H Wagner, and R Erhard, and P Peters, and H Losse
January 1980, Nephron,
F Wessels, and H Wagner, and R Erhard, and P Peters, and H Losse
January 1982, The Medical letter on drugs and therapeutics,
F Wessels, and H Wagner, and R Erhard, and P Peters, and H Losse
April 1983, Recenti progressi in medicina,
F Wessels, and H Wagner, and R Erhard, and P Peters, and H Losse
January 1976, Verhandlungen der Deutschen Gesellschaft fur Innere Medizin,
F Wessels, and H Wagner, and R Erhard, and P Peters, and H Losse
July 1978, Archives des maladies du coeur et des vaisseaux,
Copied contents to your clipboard!